Rezolute

🇺🇸United States

Introduction: Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

RZ358 Treatment for Congenital Hyperinsulinism

Phase 3

Recruiting

Interventions: Drug: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC
Drug: RZ358 (10 mg/kg) or Placebo + SOC
Drug: RZ358 (5-10 mg/kg) + SOC

Locations: 🇧🇬
Rezolute Investigative Site, Varna, Bulgaria, Varna, Bulgaria
🇩🇪
Rezolute Investigative Site, Berlin, Germany, Berlin, Germany
🇩🇰
Rezolute Investigative Site, Odense, Denmark, Odense, Denmark

Phase 2

Active, not recruiting

Locations: 🇺🇸
Rezolute Investigative Site, Modesto, California, Modesto, California, United States
🇺🇸
Rezolute Investigative Site, Santa Barbara, CA, Santa Barbara, California, United States
🇺🇸
Rezolute Investigative Site, Coral Springs, Florida, Coral Springs, Florida, United States

Phase 2

Completed

Interventions: Drug: RZ358 Sequential Group Cohort 3
Drug: RZ358 Sequential Group Cohort 1
Drug: RZ358 Sequential Group Cohort 2
Drug: RZ358 Sequential Group Cohort 4

Locations: 🇧🇬
Medical University of Varna UMHAT "St. Marina", Varna, Bulgaria
🇧🇬
SHAT Children diseases "Prof. Dr. Ivan Mitov", Sofia, Bulgaria
🇩🇰
Odense University Hospital, Odense, Denmark